BioNTech Shares Show Resilience Amidst Legal Challenge

Investors demonstrated notable composure as news broke of a significant patent lawsuit against BioNTech. The German biotech firm, alongside its partners Pfizer and Moderna, was named in a legal action filed by Bayer on January 7, 2026. The complaint alleges infringement concerning mRNA technology. Despite the potential for such litigation to unsettle the biotechnology sector, BioNTech’s stock performance on Friday told a different story.

Trading activity on January 9 revealed a market largely unfazed by the legal developments. On the NASDAQ, BioNTech shares closed at $99.85, registering a daily gain of 1.01 percent. The equity showed similar strength on Germany’s Tradegate exchange, advancing 1.24 percent to approximately €85.90. NASDAQ trading volume surpassed one million shares, indicating Read more...